Acadia Pharmaceuticals | ACAD - Net Income


Acadia Pharmaceuticals reported $71.78M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
Acadia Pharmaceuticals USD 71.78M 45.11M Sep/2025
ALKERMES USD 82.76M 4.34M Sep/2025
Alnylam Pharmaceuticals USD 186.42M 64.66M Dec/2025
Biogen USD 466.5M 168.3M Sep/2025
BioMarin Pharmaceutical USD -46.57M 15.83M Dec/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Cara Therapeutics USD -4.91M 2.77M Mar/2025
Corcept Therapeutics USD 19.67M 15.48M Sep/2025
Cytokinetics USD -306.18M 171.81M Sep/2025
Eisai JPY 17.18B 7.02B Dec/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Incyte USD 299.28M 124.89M Dec/2025
J&J USD 5.12B 36M Dec/2025
Moderna USD -200M 625M Sep/2025
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Pfizer USD -1.65B 5.19B Dec/2025
Prothena USD -36.54M 89.23M Sep/2025
PTC Therapeutics USD -134.96M 150.86M Dec/2025
Sarepta Therapeutics USD -179.95M 376.84M Sep/2025
Ultragenyx Pharmaceutical USD -129M 51.41M Dec/2025
Vanda Pharmaceuticals USD -18.9M 13.58M Dec/2024
Vertex Pharmaceuticals USD 1.19B 108.2M Dec/2025